Mangoceuticals
MGRX
18 hedge funds and large institutions have $298K invested in Mangoceuticals in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
0% more funds holding
Funds holding: 18 → 18 (0)
84% less capital invested
Capital invested by funds: $1.88M → $298K (-$1.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.3K |
| 2 |
VF
Virtu Financial
New York
|
+$13.2K |
| 3 |
Jane Street
New York
|
+$12.1K |
| 4 |
SG
StoneX Group
New York
|
+$7.68K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$6.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.14M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$34.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$104 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$79 |
| 5 |
Citigroup
New York
|
-$1 |
MGRX Hedge Fund Activity: Q1 2026 in Review
18 of the 8,195 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q1 2026, worth a combined $298K — down 84% from $1.88M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MGRX positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $41.3K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.14M sold.
- 18 institutional investors held Mangoceuticals (MGRX) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $298K of Mangoceuticals stock for Q1 2026, down 84% quarter-over-quarter.
- 5 funds opened new Mangoceuticals positions in Q1 2026 and 4 closed out, a net change of +1 holder.
- The largest Mangoceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $41.3K added.
- The largest Mangoceuticals seller in Q1 2026 was Armistice Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q1 2026.